{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:35:35Z","timestamp":1778254535878,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"8930","license":[{"start":{"date-parts":[[1994,10,1]],"date-time":"1994-10-01T00:00:00Z","timestamp":780969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1994,10]]},"DOI":"10.1016\/s0140-6736(94)90628-9","type":"journal-article","created":{"date-parts":[[2003,10,9]],"date-time":"2003-10-09T05:21:59Z","timestamp":1065676919000},"page":"1105-1110","source":"Crossref","is-referenced-by-count":1288,"title":["Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis"],"prefix":"10.1016","volume":"344","author":[{"given":"M.J","family":"Elliott","sequence":"first","affiliation":[]},{"given":"R.N","family":"Maini","sequence":"additional","affiliation":[]},{"given":"M","family":"Feldmann","sequence":"additional","affiliation":[]},{"given":"J.R","family":"Kalden","sequence":"additional","affiliation":[]},{"given":"C","family":"Antoni","sequence":"additional","affiliation":[]},{"given":"J.S","family":"Smolen","sequence":"additional","affiliation":[]},{"given":"B","family":"Leeb","sequence":"additional","affiliation":[]},{"given":"F.C","family":"Breedveld","sequence":"additional","affiliation":[]},{"given":"J.D","family":"Macfarlane","sequence":"additional","affiliation":[]},{"given":"J.A","family":"Bijl","sequence":"additional","affiliation":[]},{"given":"J.N","family":"Woody","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(94)90628-9_BIB1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0140-6736(93)92628-7","article-title":"Clinical managment of rheumatoid arthritis","volume":"341","author":"Brooks","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"ii","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB3","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/eji.1830211039","article-title":"Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumour necrosis factor &agr","volume":"21","author":"Haworth","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB4","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumour necrosis factor ameloriates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB5","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","article-title":"Involvement of endogenous tumour necrosis factor \u03b1 and transforming growth factor \u03b2 during induction of collagen type II arthritis in mice","volume":"89","author":"Thorbecke","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB6","first-page":"144","article-title":"Does TNF\u03b1 have a pivotal role in the cytokine network in rheumatoid arthritis?","author":"Feldmann","year":"1993"},{"issue":"suppl 8","key":"10.1016\/S0140-6736(94)90628-9_BIB7","first-page":"S173","article-title":"TNF\u03b1 in rheumatoid arthritis and prospects of anti-TNF therapy","volume":"11","author":"Maim","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimaeric monoclonal antibodies to tumour necrosis factor &agr","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"Steinbrocker","year":"1949","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterisation of a mouse-human chimaeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.1780330403","article-title":"Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo","volume":"33","author":"Paulus","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB14","first-page":"37","article-title":"EULAR standing committee for international clinical studies including therapeutic trials (ESCISIT)","volume":"23","author":"Smolen","year":"1994","journal-title":"Rheumatol Eur"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumour necrosis factor \u03b1 (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/art.1780360907","article-title":"DAB486IL-2 fusion toxin in refractory rheumatoid arthritis","volume":"36","author":"Sewell","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB17","first-page":"S39","article-title":"Double blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB486IL-2) in patients with refractory rheumatoid arthritis (RA)","volume":"36","author":"Moreland","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000236718","article-title":"New directions for biological therapy in rheumatoid arthritis","volume":"104","author":"Elliott","year":"1994","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB19","first-page":"S39","article-title":"Minimal efficacy of a depleting chimaeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)","volume":"36","author":"Moreland","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB20","unstructured":"Pa van der Lubbe, Ba Dijkmans, Hm Markusse, et al., Lack of clinical effect of CD4 monoclonal antibody therapy in early rheumatoid arthritis: a placebo controlled trial, Arthritis Rheum ((in press))."},{"key":"10.1016\/S0140-6736(94)90628-9_BIB21","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.4049\/jimmunol.143.9.2894","article-title":"Evidence that tumour necrosis factor has an important role in antibacterial resistance","volume":"143","author":"Havell","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0092-8674(93)90134-C","article-title":"Mice deficient for the 55kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection","volume":"73","author":"Pfeffer","year":"1993","journal-title":"Cell"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","article-title":"Chronic exposure to TNF\u03b1 in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex: reversal in vivo by anti-TNF\u03b1 antibody in patients with rheumatoid arthritis","volume":"94","author":"Cope","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB24","first-page":"171","article-title":"Mechanisms of erythroid suppression in the anemia of chronic disease","volume":"18","author":"Roodman","year":"1987","journal-title":"Blood Cells"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V74.1.130.130","article-title":"Chronic exposure to tumour necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice","volume":"74","author":"Johnson","year":"1989","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(94)90628-9_BIB26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn's disease","volume":"342","author":"Derkx","year":"1993","journal-title":"Lancet"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673694906289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673694906289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T02:18:02Z","timestamp":1682561882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673694906289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,10]]},"references-count":26,"journal-issue":{"issue":"8930","published-print":{"date-parts":[[1994,10]]}},"alternative-id":["S0140673694906289"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(94)90628-9","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[1994,10]]}}}